Understanding and exploiting the roles of O-GlcNAc in neurodegenerative diseases
Open Access
- 31 October 2023
- journal article
- review article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (12) , 105411
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01GM114537)
- NIGMS (R01GM125939)
- Michael J. Fox Foundation for Parkinson's Research
- Canadian Institutes of Health Research (PJT-156202)
- Natural Sciences and Engineering Research Council of Canada (RGPIN-05426)
- Canada Research Chairs
This publication has 186 references indexed in Scilit:
- The Permeability of Reconstituted Nuclear Pores Provides Direct Evidence for the Selective Phase ModelCell, 2012
- The Amyloid State of Proteins in Human DiseasesCell, 2012
- Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron DeathNeuron, 2011
- Molecular chaperones in protein folding and proteostasisNature, 2011
- Inhibition of O-GlcNAcase Using a Potent and Cell-Permeable Inhibitor Does Not Induce Insulin Resistance in 3T3-L1 AdipocytesChemistry & Biology, 2010
- Elevation of Global O-GlcNAc in Rodents Using a Selective O-GlcNAcase Inhibitor Does Not Cause Insulin Resistance or Perturb GlucohomeostasisChemistry & Biology, 2010
- Solid-state NMR and SAXS studies provide a structural basis for the activation of αB-crystallin oligomersNature Structural & Molecular Biology, 2010
- Glycopeptide-specific monoclonal antibodies suggest new roles for O-GlcNAcNature Chemical Biology, 2010
- GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylationBiochemical Journal, 2009
- Direct In-Gel Fluorescence Detection and Cellular Imaging of O-GlcNAc-Modified ProteinsJournal of the American Chemical Society, 2008